The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?

Amos Kirilovsky, Carine El Sissy, Guy Zeitoun, Florence Marliot, Nacilla Haicheur, Christine Lagorce-Pagès, Julien Taieb, Mehdi Karoui, Petra Custers, Edina Dizdarevic, Soledad Iseas, Torben Frøstrup Hansen, Lars Henrik Jensen, Geerard L. Beets, Jean Pierre Gérard, Mireia Castillo-Martin, Nuno L. Figueiredo, Angelita Habr-Gama, Rodrigo O. Perez, Jérôme GalonFranck Pagès*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

13 Downloads (Pure)


Because of the function and anatomical environment of the rectum, therapeutic strategies for local advanced rectal cancer (LARC) must deal with two challenging stressors that are a high-risk of local and distal recurrences and a high-risk of poor quality of life (QoL). Over the last three decades, advances in screening tests, therapies, and combined-modality treatment options and strategies have improved the prognosis of patients with LARC. However, owing to the heterogeneous nature of LARC and genetic status, the patient may not respond to a specific therapy and may be at increased risk of side-effects without the life-prolonging benefit. Indeed, each therapy can cause its own side-effects, which may worsen by a combination of treatments resulting in long-term poor QoL. In LARC, QoL has become even more essential with the increasing incidence of rectal cancer in young individuals. Herein, we analyzed the value of the Immunoscore-Biopsy (performed on tumor biopsy at diagnosis) in predicting outcomes, alone or in association with clinical and imaging data, for each therapy used in LARC.
Original languageEnglish
Pages (from-to)18-31
Publication statusPublished - 2022


Dive into the research topics of 'The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?'. Together they form a unique fingerprint.

Cite this